Literature DB >> 821573

Antibiotics in biliary surgery.

A A Gunn.   

Abstract

Infection is the major cause of morbidity following biliary surgery and it has been shown that the patients with infected bile can be detected preoperatively. This paper presents the results of a controlled trial comparing patients expected to have infected bile who received surgical treatment with and without antibiotic therapy. The results showed a reduction in the incidence and severity of complications in the treated group.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 821573     DOI: 10.1002/bjs.1800630817

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  6 in total

1.  Antimicrobial prophylaxis in biliary surgery.

Authors:  A A Gunn
Journal:  World J Surg       Date:  1982-05       Impact factor: 3.352

2.  Intraoperative concentrations of ofloxacin in serum, bile fluid, and gallbladder wall tissue.

Authors:  A Chin; M P Okamoto; M A Gill; D A Sclar; T V Berne; A E Yellin; P N Heseltine; M D Appleman
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

3.  Infectious complications after 809 biliary tract operations and results of a prospective randomized single-blind study comparing cefoxitin versus ampicillin plus an inhibitor of beta-lactamases.

Authors:  D H Wittmann; P Koltowski; J Oleszkiewicz; A P Walker
Journal:  Infection       Date:  1990 Jan-Feb       Impact factor: 3.553

4.  Prophylactic co-trimoxazole in biliary surgery.

Authors:  C Morran; W McNaught; C S McArdle
Journal:  Br Med J       Date:  1978-08-12

5.  Prophylactic antibiotics for patients undergoing elective biliary tract surgery: a prospective randomized study of cefotiam and cefoperazone.

Authors:  N Shinagawa; Y Tachi; S Ishikawa; J Yura
Journal:  Jpn J Surg       Date:  1987-01

6.  Mezlocillin prophylaxis in biliary tract surgery. Results of a retrospective and a prospective trial.

Authors:  U F Gruber; R Elke; M Widmer
Journal:  Infection       Date:  1982       Impact factor: 3.553

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.